SERMs to help prevent postmenopausal bone loss in women

An imbalance in the bone remodeling cycle caused bone loss that eventually leads to osteoporosis and fracture risk, and among selective estrogen-receptor modulators (SERMs), raloxifen (Evista) may be considered an effective alterative for the prevention of postmenopausal bone loss in women, according to InternationalOsteoporosisFederation Chairman PierreDelma.

Speaking to participants on Aug...